AU2017372856B9 - Preservation of immune response during chemotherapy regimens - Google Patents

Preservation of immune response during chemotherapy regimens Download PDF

Info

Publication number
AU2017372856B9
AU2017372856B9 AU2017372856A AU2017372856A AU2017372856B9 AU 2017372856 B9 AU2017372856 B9 AU 2017372856B9 AU 2017372856 A AU2017372856 A AU 2017372856A AU 2017372856 A AU2017372856 A AU 2017372856A AU 2017372856 B9 AU2017372856 B9 AU 2017372856B9
Authority
AU
Australia
Prior art keywords
inhibitor
cdk4
day
administering
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017372856A
Other languages
English (en)
Other versions
AU2017372856B2 (en
AU2017372856A1 (en
Inventor
Anne Y. LAI
Patrick Joseph Roberts
Jessica A. SORRENTINO
Jay C. Strum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacosmos Holding AS
Original Assignee
Pharmacosmos Holding AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62491342&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2017372856(B9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacosmos Holding AS filed Critical Pharmacosmos Holding AS
Publication of AU2017372856A1 publication Critical patent/AU2017372856A1/en
Priority to AU2023282168A priority Critical patent/AU2023282168B2/en
Priority to AU2023282170A priority patent/AU2023282170B2/en
Publication of AU2017372856B2 publication Critical patent/AU2017372856B2/en
Application granted granted Critical
Publication of AU2017372856B9 publication Critical patent/AU2017372856B9/en
Priority to AU2025242155A priority patent/AU2025242155A1/en
Assigned to PHARMACOSMOS HOLDING A/S reassignment PHARMACOSMOS HOLDING A/S Request for Assignment Assignors: G1 THERAPEUTICS, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU2017372856A 2016-12-05 2017-12-05 Preservation of immune response during chemotherapy regimens Active AU2017372856B9 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2023282168A AU2023282168B2 (en) 2016-12-05 2023-12-11 Preservation of immune response during chemotherapy regimens
AU2023282170A AU2023282170B2 (en) 2016-12-05 2023-12-11 Preservation of immune response during chemotherapy regimens
AU2025242155A AU2025242155A1 (en) 2016-12-05 2025-10-01 Preservation of immune response during chemotherapy regimens

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662430302P 2016-12-05 2016-12-05
US62/430,302 2016-12-05
US201762479605P 2017-03-31 2017-03-31
US62/479,605 2017-03-31
PCT/US2017/064775 WO2018106729A1 (en) 2016-12-05 2017-12-05 Preservation of immune response during chemotherapy regimens

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2023282170A Division AU2023282170B2 (en) 2016-12-05 2023-12-11 Preservation of immune response during chemotherapy regimens
AU2023282168A Division AU2023282168B2 (en) 2016-12-05 2023-12-11 Preservation of immune response during chemotherapy regimens

Publications (3)

Publication Number Publication Date
AU2017372856A1 AU2017372856A1 (en) 2019-06-06
AU2017372856B2 AU2017372856B2 (en) 2023-12-14
AU2017372856B9 true AU2017372856B9 (en) 2024-01-04

Family

ID=62491342

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2017372856A Active AU2017372856B9 (en) 2016-12-05 2017-12-05 Preservation of immune response during chemotherapy regimens
AU2023282170A Active AU2023282170B2 (en) 2016-12-05 2023-12-11 Preservation of immune response during chemotherapy regimens
AU2023282168A Active AU2023282168B2 (en) 2016-12-05 2023-12-11 Preservation of immune response during chemotherapy regimens
AU2025242155A Pending AU2025242155A1 (en) 2016-12-05 2025-10-01 Preservation of immune response during chemotherapy regimens

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2023282170A Active AU2023282170B2 (en) 2016-12-05 2023-12-11 Preservation of immune response during chemotherapy regimens
AU2023282168A Active AU2023282168B2 (en) 2016-12-05 2023-12-11 Preservation of immune response during chemotherapy regimens
AU2025242155A Pending AU2025242155A1 (en) 2016-12-05 2025-10-01 Preservation of immune response during chemotherapy regimens

Country Status (12)

Country Link
US (2) US11529352B2 (enExample)
EP (1) EP3548030A4 (enExample)
JP (4) JP2019536805A (enExample)
KR (4) KR20190092478A (enExample)
CN (3) CN117562905A (enExample)
AU (4) AU2017372856B9 (enExample)
BR (1) BR112019011410A2 (enExample)
CA (1) CA3045465A1 (enExample)
IL (4) IL317919A (enExample)
MX (2) MX2019006523A (enExample)
NZ (2) NZ753631A (enExample)
WO (1) WO2018106729A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS59790B1 (sr) * 2013-03-15 2020-02-28 G1 Therapeutics Inc Privremena zaštita normalnih ćelija tokom hemoterapije
HRP20202030T1 (hr) 2014-04-30 2021-02-19 Fujifilm Corporation Liposomska kompozicija i postupak za njeno dobivanje
CN106397592A (zh) * 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
WO2018005863A1 (en) * 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
IL317919A (en) 2016-12-05 2025-02-01 G1 Therapeutics Inc Preservation of immune response during chemotherapy regimens
CA3048057A1 (en) 2017-01-06 2018-07-12 G1 Therapeutics, Inc. Combination therapy for the treatment of cancer
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
AU2018246024B2 (en) 2017-03-31 2020-08-06 Fujifilm Corporation Liposome composition and pharmaceutical composition
WO2019054865A1 (en) * 2017-09-14 2019-03-21 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) T-cell based immunotherapy
WO2019108589A1 (en) * 2017-11-30 2019-06-06 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for treating cancer
KR20200108867A (ko) 2018-01-08 2020-09-21 쥐원 쎄라퓨틱스, 인크. G1t38 우수한 투여 요법
CN112218634A (zh) * 2018-04-09 2021-01-12 G1治疗公司 具有驱动致癌突变的癌症的治疗
TWI874322B (zh) 2018-06-20 2025-03-01 日商富士軟片股份有限公司 包含內含吉西他濱之脂質體組成物及免疫檢查點抑制劑之組合醫藥
EP3811931B1 (en) * 2018-06-20 2024-07-03 FUJIFILM Corporation Combination medication containing liposome composition encapsulating drug and immune checkpoint inhibitor
US20220073638A1 (en) * 2018-09-19 2022-03-10 INSERM (Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
EP3861987A4 (en) 2018-10-01 2021-09-15 FUJIFILM Corporation COMBINATION DRUG CONTAINING A LIPOSOME COMPOSITION ENCAPSULATING A DRUG AND A PLATINUM PREPARATION
JP2022506829A (ja) * 2018-11-09 2022-01-17 ジー１、セラピューティクス、インコーポレイテッド エリブリンと選択的ｃｄｋ４／６阻害剤との組合せを使用する癌の処置のための治療レジメン
US20220288067A1 (en) * 2019-04-24 2022-09-15 The Trustees Of The University Of Pennsylvania Treatment of cancer with cdk inhibitors
KR20220004744A (ko) * 2019-05-03 2022-01-11 제넨테크, 인크. 항-pd-l1 항체를 이용하여 암을 치료하는 방법
EP3986410A4 (en) * 2019-06-18 2023-06-28 G1 Therapeutics, Inc. Patient selection for enhancement of anti-tumor immunity in cancer patients
EP4058824A4 (en) 2019-11-12 2022-12-28 Pointcloud Inc. TWO-WAY LIGHT DETECTION AND DISTANCE MEASUREMENT SYSTEM
WO2021110122A1 (zh) * 2019-12-05 2021-06-10 基石药业（苏州）有限公司 Cdk4/6抑制剂的组合疗法
MX2022014573A (es) 2020-05-19 2022-12-15 G1 Therapeutics Inc Compuestos inhibidores de cinasa dependiente de ciclina para el tratamiento de trastornos medicos.
CN120398896A (zh) * 2020-06-15 2025-08-01 海南先声再明医药股份有限公司 曲拉西利的形态及其制造方法
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
WO2022087018A1 (en) * 2020-10-19 2022-04-28 G1 Therapeutics, Inc. Improved fluorouracil-based multi-agent chemotherapy for treatment of metastatic colorectal cancer
CN116583295A (zh) * 2020-12-07 2023-08-11 印地安纳大学理事会 使用白术内酯i使癌细胞对免疫攻击敏感的方法
CN113788837B (zh) * 2021-08-02 2022-08-26 深圳湾实验室坪山生物医药研发转化中心 Trilaciclib的合成方法
WO2023068220A1 (ja) * 2021-10-18 2023-04-27 株式会社Preferred Networks 予測方法及びバイオマーカー
US20250170238A1 (en) * 2022-02-25 2025-05-29 Daniel White Anti-alarmin binding molecules and treatment of pneumonitis
JP2025527861A (ja) * 2022-09-02 2025-08-22 アールエス・オンコロジー，エルエルシー チオストレプトン投薬レジメン
WO2024216208A2 (en) * 2023-04-14 2024-10-17 Concarlo Therapeutics, Inc. Brk peptides and methods of use
WO2024238476A2 (en) * 2023-05-15 2024-11-21 Cedars-Sinai Medical Center Y chromosome gene signature as a target for cancer therapy in combination with immunotherapy
CN117511855B (zh) * 2023-11-09 2024-11-19 南京医科大学 Epha抑制剂在诱导减数分裂中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016126889A1 (en) * 2015-02-03 2016-08-11 G1 Therapeutics, Inc. Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0327380D0 (en) 2003-11-25 2003-12-31 Cyclacel Ltd Method
RU2447891C2 (ru) 2006-04-05 2012-04-20 Новартис Аг Комбинации терапевтических средств, предназначенные для лечения рака
JP2010514689A (ja) 2006-12-22 2010-05-06 ノバルティス アーゲー 癌、炎症およびウイルス感染症の処置のためのｃｄｋ阻害剤としてのヘテロアリール−ヘテロアリール化合物
WO2009061345A2 (en) 2007-11-07 2009-05-14 Cornell Research Foundation, Inc. Targeting cdk4 and cdk6 in cancer therapy
ES2964764T3 (es) 2008-07-29 2024-04-09 Nerviano Medical Sciences Srl Combinación terapéutica que comprende un inhibidor de cdk y oxaliplatino
BRPI0917791B1 (pt) 2008-08-22 2022-03-22 Novartis Ag Compostos de pirrolopirimidina como inibidores de cdk, bem como composição farmacêutica e combinação
EP2341911A4 (en) 2008-10-01 2012-10-24 Univ North Carolina HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE INHIBITORS OF KINASES DEPENDENT ON CYCLINES 4/6
WO2010051127A2 (en) 2008-10-01 2010-05-06 The University Of North Carolina At Chapel Hill Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
AU2010248886A1 (en) 2009-05-13 2011-12-01 The University Of North Carolina At Chapel Hill Cyclin dependent kinase inhibitors and methods of use
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
ES2592515T3 (es) 2010-10-25 2016-11-30 G1 Therapeutics, Inc. Inhibidores de CDK
CN103635189B (zh) 2011-07-01 2016-05-04 诺华股份有限公司 用于治疗癌症的含有cdk4/6抑制剂和pi3k抑制剂的联合治疗
AU2013239816B2 (en) 2012-03-29 2017-08-24 G1 Therapeutics, Inc. Lactam kinase inhibitors
EP2841417A1 (en) 2012-04-26 2015-03-04 Francis Xavier Tavares Synthesis of lactams
HK1222766A1 (zh) 2013-03-15 2017-07-14 G1治疗公司 高效的抗赘生剂和抗增生剂
RS59790B1 (sr) 2013-03-15 2020-02-28 G1 Therapeutics Inc Privremena zaštita normalnih ćelija tokom hemoterapije
US20140274896A1 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
US20160287592A1 (en) 2013-04-08 2016-10-06 Pharmacyclics Llc Ibrutinib combination therapy
CN105682683A (zh) * 2013-08-02 2016-06-15 阿杜罗生物科技控股有限公司 结合cd27激动剂以及免疫检查点抑制以用于免疫刺激
WO2015061407A1 (en) 2013-10-24 2015-04-30 Francis Xavier Tavares Process for synthesis of lactams
JOP20200094A1 (ar) * 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
ES2939760T3 (es) * 2014-03-15 2023-04-26 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico para antígenos
US20150297606A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic Lactams for Use in the Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
CA2949121A1 (en) 2014-05-15 2015-11-19 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
CA2960824A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
EP3662903A3 (en) 2014-10-03 2020-10-14 Novartis AG Combination therapies
RU2726996C1 (ru) * 2014-12-16 2020-07-17 Бристол-Маерс Сквибб Компани Применение ингибиторов иммунных контрольных точек при новообразованиях центральной нервной системы
EP3471717A4 (en) 2016-06-20 2020-01-22 Kura Oncology, Inc. Treatment of squamous cell carcinomas with inhibitors of erk
EP3538148A1 (en) 2016-11-08 2019-09-18 Dana-Farber Cancer Institute Compositions and methods of modulating anti-tumor immunity
US20190275049A1 (en) 2016-11-16 2019-09-12 Pfizer Inc. Combination of an EGFR T790M Inhibitor and a CDK Inhibitor for the Treatment of Non-Small Cell Lung Cancer
CA3043288A1 (en) 2016-11-30 2018-06-07 Oncotyrol Center For Personalized Cancer Medicine Gmbh 3-amino-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones as cyclin dependent kinase inhibitors
IL317919A (en) 2016-12-05 2025-02-01 G1 Therapeutics Inc Preservation of immune response during chemotherapy regimens
US20200108066A1 (en) 2017-03-30 2020-04-09 Shorn Goel Methods for modulating regulatory t cells and immune responses using cdk4/6 inhibitors
WO2019108589A1 (en) 2017-11-30 2019-06-06 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for treating cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016126889A1 (en) * 2015-02-03 2016-08-11 G1 Therapeutics, Inc. Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANNALS OF ONCOLOGY, 2016.10, VOL.27, NO.SUPPLE.6, P.VI496, JPN6021048138, ISSN: 0004654418 *
J. E. BISI ET AL: "Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression", MOLECULAR CANCER THERAPEUTICS, vol. 15, no. 5, 29 January 2016 (2016-01-29), US, pages 783 - 793 *
LIMA CAIO MAX S ROCHA ET AL: "G1T28, a cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin for extensive stage small cell lung cancer (ES-SCLC): preliminary results", CANCER RESEARCH, vol. 76, no. Suppl *

Also Published As

Publication number Publication date
KR20240023677A (ko) 2024-02-22
NZ795224A (en) 2025-10-31
IL303038A (en) 2023-07-01
IL303038B1 (en) 2024-04-01
IL311265A (en) 2024-05-01
AU2023282168A1 (en) 2024-01-04
AU2017372856B2 (en) 2023-12-14
RU2019120160A3 (enExample) 2021-04-07
NZ753631A (en) 2023-07-28
JP2023182577A (ja) 2023-12-26
JP2019536805A (ja) 2019-12-19
AU2017372856A1 (en) 2019-06-06
KR20240024296A (ko) 2024-02-23
AU2023282168B2 (en) 2025-10-09
IL266870A (en) 2019-08-29
EP3548030A4 (en) 2020-08-12
WO2018106729A1 (en) 2018-06-14
CN117562905A (zh) 2024-02-20
MX2019006523A (es) 2019-10-15
BR112019011410A2 (pt) 2019-10-22
CN117530948A (zh) 2024-02-09
US20190321370A1 (en) 2019-10-24
KR20240023676A (ko) 2024-02-22
IL317919A (en) 2025-02-01
CA3045465A1 (en) 2018-06-14
KR20190092478A (ko) 2019-08-07
MX2023006991A (es) 2023-06-26
RU2019120160A (ru) 2021-01-11
US11529352B2 (en) 2022-12-20
AU2025242155A1 (en) 2025-10-23
AU2023282170B2 (en) 2025-10-09
JP7710496B2 (ja) 2025-07-18
AU2023282170A1 (en) 2024-01-04
CN110035759A (zh) 2019-07-19
IL303038B2 (en) 2024-08-01
JP2022116301A (ja) 2022-08-09
EP3548030A1 (en) 2019-10-09
JP7483791B2 (ja) 2024-05-15
JP2025148426A (ja) 2025-10-07
US20230302001A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
JP7710496B2 (ja) 化学療法計画中の免疫応答の保護
WO2020206035A1 (en) Treatment of cdk4/6 inhibitor resistant neoplastic disorders
KR20200108867A (ko) G1t38 우수한 투여 요법
WO2023034336A2 (en) Improved treatments for advanced/metastatic cancers with checkpoint inhibitor resistance or resistance susceptibility
WO2019222521A1 (en) Cdk inhibitors for the treatment of neoplastic disorders
JP2025525376A (ja) 医学的治療用のサイクリン依存性キナーゼ２阻害剤
RU2779478C2 (ru) Сохранение иммунного ответа во время химиотерапевтических схем
EA043297B1 (ru) Применение ингибитора cdk4/6 в сохранении иммунного ответа во время химиотерапевтических схем
BR122025020789A2 (pt) Uso um inibidor seletivo da cinase dependente da ciclina 4/6 (cdk4/6)
HK40012319A (en) Preservation of immune response during chemotherapy regimens
CN118234496A (zh) 检查点抑制剂耐药或耐药易感性的晚期/转移性癌症的改善治疗
HK40041180A (en) G1t38 superior dosage regimes

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: PHARMACOSMOS HOLDING A/S

Free format text: FORMER OWNER(S): G1 THERAPEUTICS, INC.